Exploring Bispecific Antibodies in Community Oncology: Overcoming Challenges and Harnessing Opportunities – [Video Podcast] Ep 52

In this episode, CANCER BUZZ speaks with Jeff Sharman, MD about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.

Bispecific antibodies (BsAbs) have transformative potential in cancer treatment and can be successfully integrated into community oncology practices. To support this integration, ACCC is committed to providing educational initiatives and support for cancer care teams to optimize care coordination. In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices. Dr. Koff sheds light on the opportunities for future partnerships with academic centers and community oncology sites to ensure there is proper infrastructure and training to safely administer bispecific antibodies.

“We’re only at the beginning here; I think that as new bispecific agents are developed, there may be other indications in which they can be used, so it will be a broader population of patients who may end up being eligible to receive these drugs.” -Jean Louise Koff

Jean Louise Koff, MD, MSc

Associate Professor, Hematology and Medical Oncology

Winship Cancer Institute of Emory University

Atlanta, GA

This podcast was developed in connection with APSHO and LRF and made possible with support by Genentech and Johnson & Johnson.

Resources